HRP20190436T1 - Mirna-124 kao biomarker - Google Patents
Mirna-124 kao biomarker Download PDFInfo
- Publication number
- HRP20190436T1 HRP20190436T1 HRP20190436TT HRP20190436T HRP20190436T1 HR P20190436 T1 HRP20190436 T1 HR P20190436T1 HR P20190436T T HRP20190436T T HR P20190436TT HR P20190436 T HRP20190436 T HR P20190436T HR P20190436 T1 HRP20190436 T1 HR P20190436T1
- Authority
- HR
- Croatia
- Prior art keywords
- mirna
- viral infection
- groups
- sample
- candidate
- Prior art date
Links
- 239000000090 biomarker Substances 0.000 title claims 4
- 108091070501 miRNA Proteins 0.000 claims 18
- 239000002679 microRNA Substances 0.000 claims 18
- 208000036142 Viral infection Diseases 0.000 claims 15
- 230000009385 viral infection Effects 0.000 claims 15
- 239000000523 sample Substances 0.000 claims 14
- 150000003248 quinolines Chemical class 0.000 claims 11
- 108091056924 miR-124 stem-loop Proteins 0.000 claims 10
- 239000012472 biological sample Substances 0.000 claims 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 8
- 229940000406 drug candidate Drugs 0.000 claims 7
- 238000000338 in vitro Methods 0.000 claims 7
- 229940125575 vaccine candidate Drugs 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 5
- 239000012530 fluid Substances 0.000 claims 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 2
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 claims 2
- 230000004071 biological effect Effects 0.000 claims 2
- 239000002853 nucleic acid probe Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- OZOGDCZJYVSUBR-UHFFFAOYSA-N 8-chloro-n-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC1=CC=C(C=CC=C2Cl)C2=N1 OZOGDCZJYVSUBR-UHFFFAOYSA-N 0.000 claims 1
- ZYUBUXKVZUJXAK-UHFFFAOYSA-N 8-chloro-n-[4-(trifluoromethyl)pyridin-2-yl]quinolin-2-amine Chemical compound FC(F)(F)C1=CC=NC(NC=2N=C3C(Cl)=CC=CC3=CC=2)=C1 ZYUBUXKVZUJXAK-UHFFFAOYSA-N 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000012228 culture supernatant Substances 0.000 claims 1
- 230000002550 fecal effect Effects 0.000 claims 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 229940125268 obefazimod Drugs 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 230000001766 physiological effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (16)
1. In vitro ili ex vivo uporaba barem jedne miRNA, navedena barem jedna miRNA je miR-124, kao biomarkera virusne infekcije, ili učinkovitosti terapijskog liječenja navedene virusne infekcije.
2. Uporaba prema zahtjevu 1, naznačena time što se izmjerena razina ekspresije navedene miR-124 u izoliranom biološkom uzorku uspoređuje s kontrolnom referentnom vrijednošću, te pri čemu je modulacija navedene izmjerene razine u odnosu na navedenu kontrolnu referentnu vrijednost indikativna za virusnu infekciju, ili za učinkovitost terapijskog liječenja navedene virusne infekcije.
3. Uporaba prema zahtjevu 1, naznačena time što se učinkovitost terapijskog liječenja navedene virusne infekcije određuje procjenom biološkog učinka spoja kandidata, kako bi se promijenila fiziološka aktivnost proteina ili stanice.
4. In vitro ili ex vivo uporaba barem jedne miRNA, navedena barem jedna miRNA je miR-124, kao biomarkera za pregled kandidata za lijek ili kandidata za cjepivo, naročito derivata kinolina, koji se smatra djelotvornim u sprječavanju i/ili liječenju virusne infekcije.
5. Uporaba prema prethodnim zahtjevima 3 ili 4, naznačena time što se mjeri razina ekspresije navedene miR-124 u izoliranom biološkom uzorku u prisutnosti navedenog kandidata u usporedbi s kontrolnom referentnom vrijednošću, te pri čemu je modulacija navedene izmjerene razine u odnosu na navedenu kontrolnu referentnu vrijednost indikativna za biološki učinak navedenog kandidata, te naročito djelotvornosti navedenog kandidata za lijek ili kandidata za cjepivo za prevenciju i/ili liječenje virusne infekcije
6. Uporaba prema zahtjevima 2 ili 5, naznačena time što je navedeni biološki uzorak odabran iz skupine koja se sastoji od uzorka biološkog tkiva, uzorka pune krvi, uzorka brisa, uzorka plazme, uzorka seruma, uzorka sline, uzorka vaginalne tekućine, uzorka sperme, uzorka faringealne tekućine, uzorka bronhijalne tekućine, uzorka fekalne tekućine, uzorka cerebrospinalne tekućine, uzorka tekućine iz suznice i uzorka supernatanta kulture tkiva.
7. Uporaba prema zahtjevima 3 do 6, naznačena time što je navedeni kandidat za lijek ili kandidat za cjepivo derivat kinolina s formulom (I):
pri čemu
- n je 1 ili 2 i R, neovisno, predstavlja vodikov atom, halogeni atom ili skupinu odabrana između skupine (C1-C3) alkil; skupine -NR1R2 u kojoj R1 i R2 su neovisno vodikov atom ili skupina (C1-C3) alkil; skupine (C1-C3) fluoroalkoksi skupine; skupine -NO2; fenoksi skupine; i skupine (C1-C4) alkoksi,
- R' je vodikov atom, halogeni atom ili skupina odabrana između (C1-C4) alkilne skupine i skupine (C1-C4) alkoksi,
- R" je vodikov atom ili skupina (C1-C4) alkil,
ili jedna od njihovih farmaceutski prihvatljivih soli.
8. Uporaba prema zahtjevima 3 do 6, naznačena time što navedeni kandidat za lijek ili kandidat za cjepivo je derivat kinolina s formulom (II):
pri čemu
- n je 1 ili 2 i R, neovisno, predstavlja vodikov atom, halogeni atom ili skupinu odabrana između skupine (C1-C3) alkil; skupine -CN; hidroksilna skupine; skupine -COOR1; skupine (C1-C3)fluoroalkil; skupine -NO2; skupine -NR1R2 gdje R1 i R2 su vodikov atom ili skupine (C1-C3)alkil; i skupine (C1-C4) alkoksi,
- R' je vodikov atom, halogeni atom ili skupina odabrana između skupine (C1-C4) alkil i skupine (C1-C4) alkoksi,
- R" je vodikov atom ili skupina (C1-C4) alkil,
ili jedna od njihovih farmaceutski prihvatljivih soli.
9. In vitro ili ex vivo uporaba barem jedne miRNA, navedena barem jedna miRNA je miR-124, kao biomarkera aktivnosti derivata kinolina ili jedne od njihovih farmaceutski prihvatljivih soli, za virusnu infekciju.
10. Uporaba prema zahtjevu 9, naznačena time što navedeni derivat kinolina ima formulu (I) kako je definirano u zahtjevu 7, ili formulu (II) kako je definirano u zahtjevu 8, ili jedna od njihovih farmaceutski prihvatljivih soli, na primjer 8-kloro-N-[4-(trifluorometoksi)fenil]kinolin-2-amin ili 8-kloro-N-[4-(trifluorometil)piridin-2-il]kinolin-2-amin.
11. Uporaba prema bilo kojem od zahtjeva 9 ili 10, naznačena time što se izmjerena razina ekspresije u izoliranom biološkom uzorku uspoređuje s kontrolnom referentnom vrijednošću, te pri čemu je povećanje navedene izmjerene razine u odnosu na navedenu kontrolnu referentnu vrijednost indikativno za aktivnost navedenog derivata kinolina.
12. In vitro ili ex vivo postupak procjenjivanja virusne infekcije kod pacijenta za kojeg se pretpostavlja da je zaražen virusom, naznačen time što sadrži barem korake:
a- mjerenje u biološkom uzorku prethodno dobivenom od navedenog pacijenta prisutnosti ili razine ekspresije barem jedne miRNA, navedena barem jedna miRNA je miR-124; i
b- uspoređivanje navedene prisutnosti ili razine ekspresije s kontrolnom referentnom vrijednošću,
pri čemu je modulirana prisutnost ili razina ekspresije navedene miRNA u odnosu na navedenu kontrolnu referentnu vrijednost indikativna za virusnu infekciju.
13. In vitro ili ex vivo postupak procjenjivanja aktivnosti derivata kinolina prema bilo kojem od zahtjeva 9 ili 10 za sprječavanje i/ili liječenje virusne infekcije kod pacijenta koji je liječen s navedenim derivatom kinolina, koji sadrži barem korake:
a- mjerenje prisutnosti ili razine ekspresije barem jedne miRNA, navedena barem jedna miRNA je miR-124, u prvom biološkom uzorku prethodno dobivenom od navedenog pacijenta prije primjene navedenog derivata kinolina i u drugom biološkom uzorku prethodno dobivenom od navedenog pacijenta prije primjene navedenog derivata kinolina; i
b- određivanje da li je navedena prisutnost ili razina ekspresije modulirana u drugom biološkom uzorku dobivenom nakon tretmana u usporedbi s drugim biološkim uzorkom dobivenim prije tretmana;
pri čemu je modulirana prisutnost ili razina ekspresije navedene miRNA indikativna za aktivnost navedenog derivata kinolina.
14. In vitro ili ex vivo postupak za probiranje kandidata za lijek ili kandidata za cjepivo za koji se pretpostavlja se da je učinkovit za sprječavanje i/ili liječenje virusne infekcije, naznačen time što sadrži barem korake:
a- obradu barem jedne izolirane stanice koja može eksprimirati barem jednu miRNA, navedena barem jedna miRNA je miR-124, s navedenim kandidatom, navedena stanica nalazi se u uvjetima pogodnim za izražavanje navedene barem jedne miRNA,
b- mjerenje prisutnosti ili razine ekspresije navedene barem jedne miRNA,
c- uspoređivanje navedene izmjerene prisutnosti ili razine ekspresije s izmjerenom ili eksprimiranom razinom navedene barem jedne miRNA u netretiranoj izoliranoj stanici,
pri čemu je modulirana prisutnost ili razina ekspresije navedene miRNA indikativna za učinkovitost navedenog kandidata za lijek ili kandidata za cjepivo za virusnu infekciju.
15. In vitro ili ex vivo upotreba izolirane sonde nukleinske kiseline koja može specifično hibridizirati s miR-124, kao dijagnostičkog sredstva za mjerenje prisutnosti ili razine ekspresije miR-124, radi dijagnosticiranja virusne infekcije ili za procjenu aktivnosti kandidata za lijek ili kandidata za cjepivo za sprječavanje i/ili liječenje virusne infekcije.
16. Uporaba prema zahtjevu 15, naznačena time što se navedena sonda nukleinske kiseline sastoji od sekvence nukleinske kiseline odabrane iz skupine koju čine SEQ ID NO: 6 do SEQ ID NO: 87.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13305053.4A EP2757161A1 (en) | 2013-01-17 | 2013-01-17 | miRNA-124 as a biomarker of viral infection |
EP14703438.3A EP2946022B1 (en) | 2013-01-17 | 2014-01-17 | Mirna-124 as a biomarker |
PCT/IB2014/058359 WO2014111892A1 (en) | 2013-01-17 | 2014-01-17 | miRNA-124 AS A BIOMARKER |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20190436T1 true HRP20190436T1 (hr) | 2019-06-14 |
Family
ID=47628077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20190436TT HRP20190436T1 (hr) | 2013-01-17 | 2019-03-04 | Mirna-124 kao biomarker |
Country Status (19)
Country | Link |
---|---|
US (1) | US11441181B2 (hr) |
EP (2) | EP2757161A1 (hr) |
JP (1) | JP6607568B2 (hr) |
KR (2) | KR102412581B1 (hr) |
CN (1) | CN105612261B (hr) |
AU (2) | AU2014206553B2 (hr) |
BR (1) | BR112015016977B1 (hr) |
CA (1) | CA2897563C (hr) |
DK (1) | DK2946022T3 (hr) |
ES (1) | ES2716104T3 (hr) |
HK (1) | HK1218766A1 (hr) |
HR (1) | HRP20190436T1 (hr) |
MX (1) | MX363726B (hr) |
PL (1) | PL2946022T3 (hr) |
PT (1) | PT2946022T (hr) |
RU (1) | RU2687366C2 (hr) |
TR (1) | TR201903401T4 (hr) |
WO (1) | WO2014111892A1 (hr) |
ZA (1) | ZA201504984B (hr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR201910781T4 (tr) | 2009-06-12 | 2019-08-21 | Abivax | Kanser tedavisi için yararlı bileşikler. |
US10253020B2 (en) | 2009-06-12 | 2019-04-09 | Abivax | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
EP2757161A1 (en) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
HRP20211839T1 (hr) * | 2013-07-05 | 2022-03-04 | Abivax | Biciklički spojevi korisni za liječenje bolesti uzrokovanih retrovirusima |
EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
EP3058940A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of viral infection |
EP3669874A1 (en) * | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of cancer |
EP3669873A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use ine the traeatment of inflammation diseases |
US20220267865A1 (en) * | 2019-02-05 | 2022-08-25 | Universidade De Santiago De Compostela | In vitro method for the diagnosis of viral infections |
EP3881844A1 (en) | 2020-03-20 | 2021-09-22 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
CN115605205A (zh) | 2020-03-20 | 2023-01-13 | Abivax公司(Fr) | 用于治疗或预防冠状病毒科感染的化合物以及用于评估冠状病毒科感染的发生的方法和用途 |
EP3884946A1 (en) | 2020-03-25 | 2021-09-29 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
WO2023126951A1 (en) * | 2022-01-03 | 2023-07-06 | Yeda Research And Development Co. Ltd. | Inhibitors of autophagy-related protein-protein interactions |
EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
EP4215196A1 (en) | 2022-01-24 | 2023-07-26 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB585362A (en) | 1944-08-31 | 1947-02-05 | Francis Henry Swinden Curd | New heterocyclic compounds |
BE486034A (hr) | 1947-11-28 | |||
DE958647C (de) | 1952-12-28 | 1957-02-21 | Hoechst Ag | Verfahren zur Herstellung von 7-Amino-2-oxy-4-methyl-chinolinen |
FR2387229A1 (fr) | 1977-04-13 | 1978-11-10 | Anvar | Dipyrido (4,3-b) (3,4-f) indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant |
FR2436786A1 (fr) | 1978-09-21 | 1980-04-18 | Anvar | Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments |
US4738710A (en) | 1979-11-19 | 1988-04-19 | Ici Australia Limited | Herbicidal alkane carboxylic acid derivatives |
FR2627493B1 (fr) | 1988-02-23 | 1991-10-31 | Sanofi Sa | Procede de preparation de derives d'isoquinoleine |
FR2645861A1 (fr) | 1989-04-17 | 1990-10-19 | Inst Nat Sante Rech Med | Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
US6180632B1 (en) | 1997-05-28 | 2001-01-30 | Aventis Pharmaceuticals Products Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
DE60008509T2 (de) | 1999-04-05 | 2004-12-16 | City Of Hope, Duarte | Neue Hemmer von fortgeschrittenen Glykosilierungsendprodukten (AGEs) |
UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
DE10013318A1 (de) | 2000-03-17 | 2001-09-20 | Merck Patent Gmbh | Formulierung enthaltend Chinoxalinderivate |
JP4223287B2 (ja) | 2001-01-22 | 2009-02-12 | メモリー・ファーマスーティカルズ・コーポレーション | 新規な化合物及び製薬上許容し得るそれらの塩並びにそれらを用いた薬剤組成物 |
US6498254B1 (en) * | 2001-10-29 | 2002-12-24 | Uniroyal Chemical Company, Inc. | Antiretroviral compounds and compositions |
MXPA04011472A (es) | 2002-05-22 | 2005-02-14 | Amgen Inc | Derivados de amino-piridina, piridina y piridazina para usarse como ligandos del receptor vaniloide para el tratamiento del dolor. |
AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
EP1539697A1 (en) | 2002-07-19 | 2005-06-15 | Memory Pharmaceutical Corporation | Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs |
FR2849474B3 (fr) | 2002-12-27 | 2004-12-03 | Olivier Jean Noel Juin | Installation de transformation de l'energie cinetique d'un fluide en energie electrique |
WO2004078731A1 (fr) | 2003-03-06 | 2004-09-16 | 'chemical Diversity Research Institute', Ltd. | Acides quinoline-carboxyliques et leurs derives et bibliotheque focalisee |
EP1601357A4 (en) | 2003-03-10 | 2007-10-03 | Schering Corp | HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS |
FR2859475A1 (fr) | 2003-09-04 | 2005-03-11 | Centre Nat Rech Scient | Utilisation de composes derives d'ellipticine et d'aza-ellipticine pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
FR2859474B1 (fr) | 2003-09-04 | 2006-01-13 | Centre Nat Rech Scient | Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
JP2007509059A (ja) | 2003-10-16 | 2007-04-12 | カイロン コーポレイション | 癌の処置のためのRafキナーゼのインヒビターとしての、2,6−二置換キナゾリン、キノキサリン、キノリンおよびイソキノリン |
WO2005051301A2 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
WO2005112930A1 (en) | 2004-05-21 | 2005-12-01 | Japan Tobacco Inc. | Combinations comprising a 4-isoquinolone derivative and anti-hiv agents |
CA2585490A1 (en) | 2004-11-12 | 2006-05-18 | Galapagos Nv | Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes |
EP1853265B1 (en) | 2005-01-28 | 2016-01-27 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Farnesyltransferase inhibitors for use in the treatment of laminopathies, cellular aging and atherosclerosis |
AU2006227833A1 (en) | 2005-03-18 | 2006-09-28 | The Regents Of The University Of California | Compounds having activity in correcting mutant-CFTR processing and uses thereof |
US20090088513A1 (en) | 2005-06-29 | 2009-04-02 | Adeka Corporation | Resin additive composition and resin composition |
WO2007042899A2 (en) * | 2005-10-10 | 2007-04-19 | Council Of Scientific And Industrial Research | Human microrna targets in hiv genome and a method of identification thereof |
RU2350650C2 (ru) * | 2006-04-17 | 2009-03-27 | Общество с ограниченной ответственностью "Биосинтез" (ООО "Биосинтез") | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pVar15-HIV-LTR, НЕСУЩАЯ КЛОНИРОВАННЫЙ ФРАГМЕНТ ГЕНОМА ВИЧ-1 ТИПА ИЗ КОНСЕРВАТИВНОГО УЧАСТКА 5'-LTR ПОСЛЕДОВАТЕЛЬНОСТИ, РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pBluKSM-HIV-LTR mod, НЕСУЩАЯ КЛОНИРОВАННЫЙ МОДИФИЦИРОВАННЫЙ ФРАГМЕНТ ЭТОГО ЖЕ УЧАСТКА ГЕНОМА ВИЧ-1 ТИПА, ТЕСТ-НАБОР ДЛЯ КОЛИЧЕСТВЕННОЙ ЭКСПРЕСС-ИДЕНТИФИКАЦИИ ГЕНОМА ВИЧ-1 ЛЮБОГО ТИПА В ПРОБЕ И СПОСОБ С ЕГО ИСПОЛЬЗОВАНИЕМ |
DK2044026T3 (da) | 2006-06-22 | 2014-06-30 | Prana Biotechnology Ltd | Fremgangsmde til behandling af cerebral glioma tumor |
FR2903312B1 (fr) | 2006-07-05 | 2008-09-26 | Univ Aix Marseille Ii | Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament |
WO2008008234A1 (en) | 2006-07-07 | 2008-01-17 | Targegen, Inc. | 2-amino-5-substituted pyrimidine inhibitors |
JP5491199B2 (ja) | 2007-01-19 | 2014-05-14 | アルデア バイオサイエンシズ,インコーポレイティド | Mekのインヒビター |
FR2912745A1 (fr) | 2007-02-19 | 2008-08-22 | Centre Nat Rech Scient | Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant |
CA2681481A1 (en) | 2007-03-16 | 2008-09-25 | Mount Sinai School Of Medicine | Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction |
TWI371445B (en) | 2007-05-17 | 2012-09-01 | Lg Chemical Ltd | New anthracene derivatives and organic electronic device using the same |
WO2008153692A2 (en) * | 2007-05-22 | 2008-12-18 | The Brigham And Women's Hospital, Inc. | Microrna expression profiling of cerebrospinal fluid |
UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
MX2010001576A (es) | 2007-08-15 | 2010-09-14 | Memory Pharm Corp | Compuestos 3´sustituidos que tienen afinidad con el receptor 5-hidroxitriptamina 6 (5-ht6). |
WO2009029617A1 (en) | 2007-08-27 | 2009-03-05 | Kalypsys, Inc. | Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors |
CA2710196A1 (en) * | 2007-12-20 | 2009-07-09 | Celgene Corporation | Use of micro-rna as a biomarker of immunomodulatory drug activity |
KR100974562B1 (ko) | 2007-12-31 | 2010-08-06 | 다우어드밴스드디스플레이머티리얼 유한회사 | 신규한 유기 발광 화합물 및 이를 발광재료로서 채용하고있는 유기 발광 소자 |
FR2926297B1 (fr) | 2008-01-10 | 2013-03-08 | Centre Nat Rech Scient | Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage. |
JP2009174368A (ja) | 2008-01-23 | 2009-08-06 | Toyota Motor Corp | 内燃機関の排気浄化装置 |
EP2271931A4 (en) * | 2008-04-25 | 2011-10-12 | Merck Sharp & Dohme | MICRO-RNA BIOMARKERS FOR TISSUE INJURIES |
US20160041153A1 (en) * | 2008-11-12 | 2016-02-11 | Kirk Brown | Biomarker compositions and markers |
JP2012520891A (ja) * | 2009-03-19 | 2012-09-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | スルホニルキノリンの製造方法 |
JP5647673B2 (ja) * | 2009-05-05 | 2015-01-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ブロモ置換キノリンの調製方法 |
EP2266972A1 (en) | 2009-06-12 | 2010-12-29 | Splicos | New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies |
US10253020B2 (en) | 2009-06-12 | 2019-04-09 | Abivax | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
MX2019008390A (es) | 2009-06-12 | 2019-09-09 | Abivax | Compuestos utiles para tratar cancer. |
TR201910781T4 (tr) | 2009-06-12 | 2019-08-21 | Abivax | Kanser tedavisi için yararlı bileşikler. |
WO2010151755A2 (en) | 2009-06-25 | 2010-12-29 | The Brigham And Women's Hospital, Inc. | TREATMENT OF INFLAMMATORY DISEASES USING miR-124 |
CA2780222C (en) * | 2009-11-04 | 2021-11-16 | Diamir, Llc | Methods of using small rna from bodily fluids for diagnosis and monitoring of neurodegenerative diseases |
EP2465502A1 (en) | 2010-12-15 | 2012-06-20 | Société Splicos | Compounds useful for treating AIDS |
WO2012118988A1 (en) * | 2011-03-01 | 2012-09-07 | The Scripps Research Institute | Direct reprogramming of human fibroblasts to functional neurons under defined conditions |
CA2848654C (en) * | 2011-09-15 | 2021-07-20 | Self-Screen B.V. | Methylation analysis on self-samples as triage tool for hpv-positive women |
WO2014055944A1 (en) | 2012-10-04 | 2014-04-10 | Oyagen, Inc. | Small molecules as anti-hiv agents that disrupt vif self-association and methods of use thereof |
EP2757161A1 (en) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
EP2975034A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | A quinoline derivative for the treatment of inflammatory diseases and AIDS |
EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
EP3059236A1 (en) | 2015-02-23 | 2016-08-24 | Abivax | A new quinoline derivative for use in the treatment and prevention of viral infections |
DK3429998T3 (da) | 2016-03-18 | 2021-11-22 | Prosynergia S A R L | Fremgangsmåde til fremstilling af quinolin-2-yl-phenylaminderivater og disses salte |
-
2013
- 2013-01-17 EP EP13305053.4A patent/EP2757161A1/en not_active Withdrawn
-
2014
- 2014-01-17 CN CN201480011638.3A patent/CN105612261B/zh active Active
- 2014-01-17 PT PT14703438T patent/PT2946022T/pt unknown
- 2014-01-17 WO PCT/IB2014/058359 patent/WO2014111892A1/en active Application Filing
- 2014-01-17 KR KR1020157022175A patent/KR102412581B1/ko active IP Right Grant
- 2014-01-17 PL PL14703438T patent/PL2946022T3/pl unknown
- 2014-01-17 EP EP14703438.3A patent/EP2946022B1/en active Active
- 2014-01-17 US US14/761,674 patent/US11441181B2/en active Active
- 2014-01-17 BR BR112015016977-5A patent/BR112015016977B1/pt active IP Right Grant
- 2014-01-17 ES ES14703438T patent/ES2716104T3/es active Active
- 2014-01-17 MX MX2015008703A patent/MX363726B/es active IP Right Grant
- 2014-01-17 AU AU2014206553A patent/AU2014206553B2/en active Active
- 2014-01-17 DK DK14703438.3T patent/DK2946022T3/en active
- 2014-01-17 RU RU2015133373A patent/RU2687366C2/ru active
- 2014-01-17 JP JP2015553212A patent/JP6607568B2/ja active Active
- 2014-01-17 CA CA2897563A patent/CA2897563C/en active Active
- 2014-01-17 TR TR2019/03401T patent/TR201903401T4/tr unknown
- 2014-01-17 KR KR1020227009514A patent/KR102575595B1/ko active IP Right Grant
-
2015
- 2015-07-10 ZA ZA2015/04984A patent/ZA201504984B/en unknown
-
2016
- 2016-06-10 HK HK16106678.8A patent/HK1218766A1/zh unknown
-
2019
- 2019-03-04 HR HRP20190436TT patent/HRP20190436T1/hr unknown
- 2019-12-19 AU AU2019283919A patent/AU2019283919A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US11441181B2 (en) | 2022-09-13 |
MX363726B (es) | 2019-04-01 |
RU2687366C2 (ru) | 2019-05-13 |
ZA201504984B (en) | 2016-09-28 |
CA2897563C (en) | 2021-08-31 |
TR201903401T4 (tr) | 2019-04-22 |
BR112015016977B1 (pt) | 2022-11-08 |
KR102575595B1 (ko) | 2023-09-06 |
CN105612261B (zh) | 2019-06-18 |
AU2014206553A1 (en) | 2015-07-23 |
KR20150109407A (ko) | 2015-10-01 |
US20150361491A1 (en) | 2015-12-17 |
WO2014111892A1 (en) | 2014-07-24 |
KR102412581B1 (ko) | 2022-06-23 |
PT2946022T (pt) | 2019-03-21 |
CA2897563A1 (en) | 2014-07-24 |
JP6607568B2 (ja) | 2019-11-20 |
DK2946022T3 (en) | 2019-04-08 |
CN105612261A (zh) | 2016-05-25 |
HK1218766A1 (zh) | 2017-03-10 |
JP2016505268A (ja) | 2016-02-25 |
AU2019283919A1 (en) | 2020-01-16 |
RU2015133373A (ru) | 2017-02-21 |
ES2716104T3 (es) | 2019-06-10 |
BR112015016977A2 (hr) | 2017-08-15 |
KR20220038551A (ko) | 2022-03-28 |
EP2946022A1 (en) | 2015-11-25 |
PL2946022T3 (pl) | 2019-06-28 |
AU2014206553B2 (en) | 2020-01-16 |
EP2946022B1 (en) | 2019-01-09 |
MX2015008703A (es) | 2016-04-15 |
EP2757161A1 (en) | 2014-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20190436T1 (hr) | Mirna-124 kao biomarker | |
Dobbelstein et al. | Exploiting replicative stress to treat cancer | |
Kameka et al. | Induction of innate immune response following infectious bronchitis corona virus infection in the respiratory tract of chickens | |
Wang et al. | Benzo (a) pyrene promotes A549 cell migration and invasion through up-regulating Twist | |
Hansen et al. | Profiling circulating miRNAs in serum from pigs infected with the porcine whipworm, Trichuris suis | |
Gerriets et al. | Feline calicivirus: a neglected cause of feline ocular surface infections? | |
CY1115640T1 (el) | Διαγνωση και αγωγη εναντι της σχιζοφρενειας | |
Pereira et al. | Natural SARS-CoV-2 infection in a free-ranging black-tailed marmoset (Mico melanurus) from an urban area in mid-west Brazil | |
Chor et al. | The role of human papillomavirus in head and neck squamous cell carcinoma: A case control study on a southern Chinese population | |
CN103314295A (zh) | Bubr1作为药物对呋咱并苯并咪唑响应的生物标记的用途 | |
CN108277279A (zh) | 一种lncRNA在诊断和/或治疗乳腺癌中的应用 | |
CN108004322A (zh) | 一种lncRNA在诊断和/或治疗肺腺癌中的应用 | |
Khodakaram-Tafti et al. | Immunohistochemical and polymerase chain reaction studies in Neospora caninum experimentally infected broiler chicken embryonated eggs | |
Mey et al. | Histomorphometric estimation of air cell development in experimental otitis media | |
Liu et al. | Expression of reversion-inducing cysteine-rich protein with kazal motifs and matrix metalloproteinase 9 in middle ear squamous cell carcinoma | |
CN104087663B (zh) | Prl-1基因在制备诊断和/或治疗肝癌产品中的应用 | |
CN108291258B (zh) | 诊断和治疗mers相关肾病 | |
JP2017525955A5 (hr) | ||
RU2016112268A (ru) | Ингибитор PI3K для лечения респираторного заболевания | |
González Aparicio et al. | Copy-back viral genomes induce a cellular stress response that interferes with viral protein expression without affecting antiviral immunity | |
CN109937260A (zh) | 提供流感感染预后的组合物和方法 | |
CN115501340B (zh) | CircPIAS1作为靶点在制备肝癌诊断试剂或治疗药物中的用途 | |
Chatterjee | Commentary: Diagnostic markers for suspected herpes simplex virus keratitis–A bridge too far | |
Zhou et al. | MicroRNA-27a acts as a novel biomarker in the diagnosis of patients with laryngeal squamous cell carcinoma | |
Begum et al. | Prevalence and comprehensive insights into molecular mechanisms in Helicobacter pylori pathogenesis. |